Arcutis Biotherapeutics Future Growth

Future criteria checks 5/6

Arcutis Biotherapeutics is forecast to grow earnings and revenue by 72.4% and 34.8% per annum respectively. EPS is expected to grow by 72.2% per annum. Return on equity is forecast to be -29.4% in 3 years.

Key information

72.4%

Earnings growth rate

72.2%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	34.8%
Future return on equity	-29.4%
Analyst coverage	Good
Last updated	07 Nov 2024

Recent future growth updates

Recent updates

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 15

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Earnings and Revenue Growth Forecasts

NasdaqGS:ARQT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	409	15	59	N/A	7
12/31/2025	268	-114	-58	N/A	7
12/31/2024	180	-161	-140	N/A	7
9/30/2024	139	-196	-168	-168	N/A
6/30/2024	132	-199	-177	-177	N/A
3/31/2024	106	-217	-199	-198	N/A
12/31/2023	60	-262	-247	-247	N/A
9/30/2023	49	-268	-262	-262	N/A
6/30/2023	12	-331	-309	-286	N/A
3/31/2023	6	-327	-304	-281	N/A
12/31/2022	4	-311	-281	-258	N/A
9/30/2022	1	-311	-262	-238	N/A
6/30/2022	N/A	-260	-212	-212	N/A
3/31/2022	N/A	-235	-186	-185	N/A
12/31/2021	N/A	-206	-176	-175	N/A
9/30/2021	N/A	-169	-156	-155	N/A
6/30/2021	N/A	-150	-149	-148	N/A
3/31/2021	N/A	-144	-139	-138	N/A
12/31/2020	N/A	-136	-113	-113	N/A
9/30/2020	N/A	-114	-97	-97	N/A
6/30/2020	N/A	-90	-74	-74	N/A
3/31/2020	N/A	-63	-57	-57	N/A
12/31/2019	N/A	-42	-43	-43	N/A
9/30/2019	N/A	-35	-32	-32	N/A
6/30/2019	N/A	-28	-24	-24	N/A
3/31/2019	N/A	-23	-19	-18	N/A
12/31/2018	N/A	-19	-14	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARQT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: ARQT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ARQT is expected to become profitable in the next 3 years.

Revenue vs Market: ARQT's revenue (34.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: ARQT's revenue (34.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARQT is forecast to be unprofitable in 3 years.

Arcutis Biotherapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 11%

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus estimates of losses per share improve by 12%

Forecast to breakeven in 2026

Consensus revenue estimates increase by 36%

Recent updates

Senior VP & Chief Medical Officer recently sold US$522k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Consensus revenue estimates increase by 11%

Forecast to breakeven in 2026

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Arcutis Canada, Inc. Receives Regulatory Approval from Health Canada for ZORYVE Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

No longer forecast to breakeven

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis Biotherapeutics, Inc. Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics, Inc. Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Consensus estimates of losses per share improve by 12%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$131k worth of stock

Forecast to breakeven in 2026

Arcutis Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for Zoryve (Roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and over

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces the U.S. Food and Drug Administration's Approval of the Supplemental New Drug Application for ZORYVE (Roflumilast) Cream

Insufficient new directors

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Senior VP & Chief Medical Officer exercised options and sold US$201k worth of stock

Senior VP & Chief Medical Officer recently sold US$435k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Consensus revenue estimates increase by 36%

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology

President notifies of intention to sell stock

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023